Eli Lilly and Company's bebtelovimab receives Emergency Use Authorization for the treatment of mild-to-moderate COVID-19
Posted:
FDA has authorized bebtelovimab for emergency use for certain non-hospitalized patients with mild-to-moderate COVID-19 at high risk of progression to severe disease for whom alternative COVID-19 treatment options approved or authorized by FDA are not accessible or clinically appropriate Bebtelovimab neutralizes Omicron as demonstrated by pseudovirus and authentic virus data.
Schizophrenia is a psychiatric disorder characterized by altered thinking and emotional patterns, hallucinations, false or irrational beliefs (i.e., delusions), cognitive deficits, and disorganized speech.
Bipolar disorder BD, on the other hand, is marked by extreme mood swings, ranging between periods of…
New joint research program combines UCSF’s advanced clinical and research teams with GE HealthCare’s technical and engineering expertise to develop solutions that directly impact patient care.
Read full article here.
Attendees
Sponsors and Exhibitors
Contact us